Secukinumab
Mechanism :
Human IgG1 monoclonal antibody selectively binds to interleukin – 17A
Indication :
- Psoriatic arthritis
- Enthesitis related arthritis
- Plaque psoriasis
- Axial Spondyloarthritis
- Active Ankylosing Spondylitis
Contraindications :
In case of hypersensitivity reactions
Check for TB before initiating
Dosing :
Psoriatic arthritis:
≥2 years - for 15-49 kg:
75 mg subcutaneously at week 0,1,2,3 and 4. Then 75 mg subcutaneously every 4 weekly.
≥50kg:
150 mg subcutaneously at week 0,1,2,3 and 4. Then 150 mg subcutaneously every 4 weekly.
Enthesitis related arthritis:
≥4 years - for 15-49 kg:
75 mg subcutaneously at week 0,1,2,3 and 4. Then 75 mg subcutaneously every 4 weekly.
Plaque psoriasis:
≥6 years:
<50 kg – 75 mg subcutaneously at week 0,1,2,3 and 4. Then 75 mg subcutaneously every 4 weekly
<50 kg – 75 mg subcutaneously at week 0,1,2,3 and 4. Then 75 mg subcutaneously every 4 weekly.
Adverse Effect :
Infections, Nasopharyngitis, diarrhoea
Interaction :
Immunosuppressants may enhance the immunosuppressive effects
Hepatic Dose :
No adjustments labelled
Pregnanacy :
Not recommended as not enough data